A 2-Part, Safety, Tolerability, and Pharmacokinetic Study of LY2775240 in Healthy Subjects

Trial Profile

A 2-Part, Safety, Tolerability, and Pharmacokinetic Study of LY2775240 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs LY 2775240 (Primary) ; Apremilast
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
    • 04 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
    • 03 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top